Biotest Aktiengesellschaft (ETR:BIO3)

Market Cap	1.39B
Revenue (ttm)	707.00M
Net Income (ttm)	68.50M
Shares Out	39.57M
EPS (ttm)	1.73
PE Ratio	16.88
Forward PE	n/a
Dividend	0.04 (0.14%)
Ex-Dividend Date	n/a

Volume	116
Average Volume	1,997
Open	28.90
Previous Close	29.20
Day's Range	28.90 - 28.90
52-Week Range	22.80 - 29.90
Beta	0.26
RSI	55.64
Earnings Date	Mar 28, 2025

About ETR:BIO3

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company’s produ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1946
• Employees: 2,426
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: BIO3